


OVA1[®] Is Improved

Reflex to 2nd Generation OVA1plus™ A Multimodal Approach

What is OVA1plus?

For women with adnexal mass, **OVA1plus** is a reflex process which first performs **OVA1** and then performs **OVERA**[®] if the **OVA1** result is in the *intermediate range*.



	OVA1 ¹ (95%CI)	Overa ² (95%CI)	OVA1plus ³ (95%CI)
Sensitivity*	92%	91%	88%
Specificity	54%	69%	72%

*96% sensitivity with clinical assessment

Premenopausal Risk² 5.0–7.0

Low < 5.0	Intermediate 5.0–7.0	Elevated > 7.0
-----------	----------------------	----------------

Postmenopausal Risk² 4.4–6.0

Low < 4.4	Intermediate 4.4–6.0	Elevated > 6.0
-----------	----------------------	----------------

What are the Benefits of OVA1plus?

Reduces false positives by reflexing **intermediate values** of OVA1

Includes **two new biomarkers** (HE4 & FSH) in OVERA reflex


Reduces unnecessary referrals **increasing specificity** to 72%

1. Bristow RE, Smith A, Zhang Z, et al., Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. *Gynecol Oncol.* 2013;128(2):252-259.
 2. Coleman RL, Herzog TJ, Chan DW, et al., Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. *Am J Obstet Gynecol* 2016;215:82.e1-11.
 3. Dunton C, Bullock RG, Twigg L et al., Improvement in MIA testing for detection of ovarian malignancy. Poster presentation at the SGO 2020 meeting.

OVA1plus Biomarkers (OVA1 and OVERA)




OVA1 is an FDA cleared multivariate index assay (MIA) that combines the results of five biomarkers and a proprietary algorithm to provide a malignancy risk index.



- **98% Negative Predictive Value**
- **96% Sensitivity (with clinical assessment)**
- **Guideline support from ACOG & SGO**



OVERA is an FDA cleared second generation multivariate index assay (MIA) that combines the results of five biomarkers and a proprietary algorithm to provide a malignancy risk index.



- **OVERA is performed when the OVA1 result is in the intermediate range**
- **Performing OVERA in this range further stratifies risk and reduces the falsely elevated rate**

OVA1 should be used in women >18yrs that have a pelvic mass to assess ovarian cancer risk prior to surgical treatment planning. It should be used in combination with clinical assessment and is not a screening test.

p: 844.277.4721 | e: aspirasupport@aspirawh.com

© 2022 Aspira Women's Health. All rights reserved. The Aspira Women's Health, OVA1 and OVERA logos are registered trademarks of Aspira Women's Health in the U.S. and other countries. Aspira Women's Health reserves the right to change this document at any time without notice and disclaims liability for editorial, pictorial or typographical errors.

